Savara, Inc. SVRA 深 沪
等待开盘 06-24 09:30:00 美东时间
5.78
+0.090
+1.58%
华盛通- 最 高5.895
- 今 开5.64
- 成交量 185.67万股
- 最 低 5.60
- 昨 收 5.69
- 总市值 11.84亿
- 52周最高 7.005
- 市盈率 静 --
- 换手率 0.91%
- 52周最低 2.14
- 委 比 -22.87%
- 总股本 2.05亿
- 历史最高 17.187
- 量 比 0.87
- 振 幅 5.18%
- 历史最低 0.69
- 每 手 1
- 风险率 1.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Savara Expands Share Capital and Updates Executive Leadership
Savara ( ($SVRA) ) has issued an update. On June 4, 2026, Savara’s stockholders...
06-09 05:48
Savara CFO to step down
Savara (SVRA) said chief financial and administrative officer Dave Lowrance will step down effective July 15 for health-related reasons. The clinical-stage biopharmaceutical company said chief operati...
06-09 04:27
Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Assume Additional Role Of CFO
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down
06-09 04:09
Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International Conference
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026,
05-20 20:17
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript
Aquestive Therapeutics (NASDAQ:AQST) held its first-quarter earnings conference...
05-14 21:09
Savara Q1 EPS $(0.15) Misses $(0.14) Estimate
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 15.38 percent. This is a 25 percent decrease over losses of $(0.12) per share from the same
05-13 05:07
Savara Announces FDA Extends Review Period For Molgramostim Inhalation Solution Biologics License Application In Autoimmune Pulmonary Alveolar Proteinosis
-- Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Months to November 22, 2026 --
04-16 04:09
Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months
-- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA),
04-07 20:13
Savara Receives European Medicines Agency Validation For Submission Of MOLBREEVI MAA In Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP;
03-30 20:16
新浪财经ESG：Savara Inc MSCI（明晟）ESG评级调降至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:29
